Replimune Group (REPL)
(Delayed Data from NSDQ)
$5.56 USD
+0.49 (9.66%)
Updated Jun 5, 2024 04:00 PM ET
After-Market: $5.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Replimune Group, Inc. [REPL]
Reports for Purchase
Showing records 141 - 160 ( 192 total )
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 8: Can An Oncolytic Virus Turn a Cold Tumor Hot?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Consider Reading Vol. 7: Observations From Treatment Responsive Cancer Patients
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal 3Q20 Financials Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
3Q19: Programs On Track With Cautious Steps Forward. Expect Data in 2020.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal 3Q Financials; Focus on Clinical Execution
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Multiple 2020 Catalysts; Leadership Change; Modulating PT to $24
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 3: Cemiplimab - Oncolytic Virus Improves ORR in CSCC
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
New CMO Search Begins With Late-Stage Product Development in Sight
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Fiscal Q2 Financials; SITC Data Supports Platform; Expanding Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
Q219 Not All Viruses Are Bad. Reiterate Buy And Raise PT To $30/Share.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Replimune Group, Inc.
Industry: Medical - Biomedical and Genetics
RP1 Opdivo Update at SITC is Encouraging, in Our View; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R